Post by tomsylver on Jul 6, 2017 14:59:35 GMT
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Scientific and Standardization Committee Meeting
GlobeNewswireâ˘July 6, 2017
SOUTH SAN FRANCISCO, Calif. , July 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.ÂŽ (PTLA) today announced that data on betrixaban and andexanet alfa, as well as presentations on disease awareness and risk, would be presented at the International Society on Thrombosis and Haemostasis (ISTH) annual meeting, which is taking place from July 8-13 in Berlin, Germany.
Details regarding the presentations follow.
Oral Presentation Details:
Presentation Title: Prevention of Exsanguination under Apixaban Anticoagulation Using Andexanet Alfa in a Polytrauma Model
Presenter: Oliver Grottke, M.D., Ph.D., RWTH University Hospital Aachen
Session Title: Bleeding Management Under Oral Anticoagulation
Presentation Date and Time: July 10, 2017 from 2:45-4:15 p.m. UTC
Session Room: London
Presentation Title: Prevalence of Major Medical Illnesses Associated with Venous Thromboembolism Risk in US Hospitals
Presenter: Alexander Cohen, MBBS, M.Sc., M.D., Kingâs College London
Session Title: DOACs and Beyond: Translational Aspects
Presentation Date and Time: July 13, 2017 from 9:30-10:45 a.m. UTC
Session Room: Berlin
Presentation Title: A Landmark Analysis of the APEX Study Comparing Extended Duration Betrixaban with Standard Duration Enoxaparin in Hospitalized Medically Ill Patients
Presenter: Alexander Cohen, MBBS, M.Sc., M.D., Kingâs College London
Session Title: Advances in Thromboprophylaxis
Presentation Date and Time: July 12, 2017 from 9:45-10:45 a.m. UTC
Location: Hall B
Presentation Title: Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of FXa Inhibitors in Patients with Acute Major Bleeding
Presenter: Janet Leeds, Ph.D., Portola Pharmaceuticals
Session Title: DOACs and Beyond: Translational Aspects
Presentation Date and Time: July 13, 2017 from 9:30-10:45 a.m. UTC
Session Room: Berlin
Poster Presentation Details:
Presentation Title: A Cross-Sectional, Multinational, Multidisciplinary Survey of Physicians Surrounding the Management of Bleeding Complications in the Setting of Direct Oral Anticoagulant Use
Presenter: Joseph Shaw, M.D., BSc, University of Ottawa
Poster Number: PB 472
Presentation Date and Time: July 10, 2017 from 12:00-1:15 p.m. UTC
Location: Exhibition Hall 2.2
Presentation Title: Impact of Evolving ACCP Guidelines on Estimates of Venous Thromboembolism Risk in US Hospitals
Presenter: Alexander Cohen, MBBS, M.Sc., M.D., Kingâs College London and Frederick Anderson, Jr., Ph.D., University of Massachusetts Medical School
Poster Number: PB 1193
Presentation Date and Time: July 11, 2017 from 12:00-1:15 p.m. UTC
Location: Exhibition Hall 4.2
Presentation Title: D-dimer in Acute Medically Ill Adults and Current Thromboprophylaxis: A Multicenter Observational Study Evaluating the Prevalence of Elevated D-dimer in Acute Medically Ill, Hospitalized Adults and Current Thromboprophylaxis Trends; the DAMIACT Study, Initial Data Analysis
Presenter: Richey Neuman, M.D., M.P.H., F.A.C.P., Portola Pharmaceuticals
Poster Number: PB 1416
Presentation Date and Time: July 11, 2017 from 12:00-1:15 p.m. UTC
Location: Exhibition Hall 6.2
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Companyâs first medicine BevyxxaÂŽ (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @portola_Pharma.
GlobeNewswireâ˘July 6, 2017
SOUTH SAN FRANCISCO, Calif. , July 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.ÂŽ (PTLA) today announced that data on betrixaban and andexanet alfa, as well as presentations on disease awareness and risk, would be presented at the International Society on Thrombosis and Haemostasis (ISTH) annual meeting, which is taking place from July 8-13 in Berlin, Germany.
Details regarding the presentations follow.
Oral Presentation Details:
Presentation Title: Prevention of Exsanguination under Apixaban Anticoagulation Using Andexanet Alfa in a Polytrauma Model
Presenter: Oliver Grottke, M.D., Ph.D., RWTH University Hospital Aachen
Session Title: Bleeding Management Under Oral Anticoagulation
Presentation Date and Time: July 10, 2017 from 2:45-4:15 p.m. UTC
Session Room: London
Presentation Title: Prevalence of Major Medical Illnesses Associated with Venous Thromboembolism Risk in US Hospitals
Presenter: Alexander Cohen, MBBS, M.Sc., M.D., Kingâs College London
Session Title: DOACs and Beyond: Translational Aspects
Presentation Date and Time: July 13, 2017 from 9:30-10:45 a.m. UTC
Session Room: Berlin
Presentation Title: A Landmark Analysis of the APEX Study Comparing Extended Duration Betrixaban with Standard Duration Enoxaparin in Hospitalized Medically Ill Patients
Presenter: Alexander Cohen, MBBS, M.Sc., M.D., Kingâs College London
Session Title: Advances in Thromboprophylaxis
Presentation Date and Time: July 12, 2017 from 9:45-10:45 a.m. UTC
Location: Hall B
Presentation Title: Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of FXa Inhibitors in Patients with Acute Major Bleeding
Presenter: Janet Leeds, Ph.D., Portola Pharmaceuticals
Session Title: DOACs and Beyond: Translational Aspects
Presentation Date and Time: July 13, 2017 from 9:30-10:45 a.m. UTC
Session Room: Berlin
Poster Presentation Details:
Presentation Title: A Cross-Sectional, Multinational, Multidisciplinary Survey of Physicians Surrounding the Management of Bleeding Complications in the Setting of Direct Oral Anticoagulant Use
Presenter: Joseph Shaw, M.D., BSc, University of Ottawa
Poster Number: PB 472
Presentation Date and Time: July 10, 2017 from 12:00-1:15 p.m. UTC
Location: Exhibition Hall 2.2
Presentation Title: Impact of Evolving ACCP Guidelines on Estimates of Venous Thromboembolism Risk in US Hospitals
Presenter: Alexander Cohen, MBBS, M.Sc., M.D., Kingâs College London and Frederick Anderson, Jr., Ph.D., University of Massachusetts Medical School
Poster Number: PB 1193
Presentation Date and Time: July 11, 2017 from 12:00-1:15 p.m. UTC
Location: Exhibition Hall 4.2
Presentation Title: D-dimer in Acute Medically Ill Adults and Current Thromboprophylaxis: A Multicenter Observational Study Evaluating the Prevalence of Elevated D-dimer in Acute Medically Ill, Hospitalized Adults and Current Thromboprophylaxis Trends; the DAMIACT Study, Initial Data Analysis
Presenter: Richey Neuman, M.D., M.P.H., F.A.C.P., Portola Pharmaceuticals
Poster Number: PB 1416
Presentation Date and Time: July 11, 2017 from 12:00-1:15 p.m. UTC
Location: Exhibition Hall 6.2
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Companyâs first medicine BevyxxaÂŽ (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @portola_Pharma.
